Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page
- Check3 days agoChange DetectedThe page’s footer/application version was updated from **v3.5.2** to **v3.5.3** for the ClinicalTrials.gov interface.SummaryDifference0.0%

- Check10 days agoChange DetectedVersion 97 (2026-04-13) adds the Contacts/Locations and Study Status sections to the record history and updates the system to Revision: v3.5.2; the prior Revision: v3.5.0 was removed on 2026-03-18.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedVersion 96 (2026-03-17) updates Study Status and Contacts/Locations; Revision: v3.5.0 is added on 2026-03-18.SummaryDifference0.2%

- Check46 days agoChange DetectedFooter Revision: v3.4.3 is added and Revision: v3.4.2 is removed, indicating a site maintenance update on the history page.SummaryDifference0.0%

- Check75 days agoChange DetectedAdded Revision: v3.4.2 to the history; removed the older site-wide notices including the lapse in government funding message and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check82 days agoChange DetectedA new 2026-01-30 version entry was added with a Study Status change and Revision: v3.4.1, and the prior 2025-12-23 entry (Revision: v3.4.0) was removed.SummaryDifference0.5%

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.